Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 9/20 | 0.38 |
| ▸ | NOS3 | P29474 | 8/20 | 0.38 |
| ▸ | NOS1 | P29475 | 7/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.35 |
| ▸ | REN | P00797 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29295852 | 0.79 | NOS3 (0.34) | NOS2NOS3NOS1POLB | |
| SCHEMBL22062964 | 0.79 | NOS3 (0.36) | NOS2NOS3NOS1BACE1POLB | |
| SCHEMBL25695984 | 0.77 | ATM (0.40) | POLB | |
| SCHEMBL21733359 | 0.76 | HSP90AA1 (0.35) | NOS2NOS3NOS1BACE1POLB | |
| SCHEMBL22062895 | 0.76 | BACE1 (0.42) | NOS2NOS3NOS1BACE1POLB | |
| SCHEMBL25696344 | 0.76 | NOS2 (0.40) | NOS2NOS3NOS1BACE1POLB | |
| SCHEMBL3176326 | 0.76 | HSD17B10 (0.34) | — | |
| SCHEMBL25951829 | 0.74 | — | — | |
| SCHEMBL20457062 | 0.74 | CYP2C19 (0.34) | — | |
| SCHEMBL24854515 | 0.74 | NOS3 (0.36) | NOS2NOS3NOS1BACE1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203060-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2023-06-29 | — | — | US | disclosed |
| US-20230203060-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2023-06-29 | — | — | US | disclosed |
| US-11236068-B2 | Fused ring compounds | GENENTECH, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20210230142-A9 | FUSED RING COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2021-07-29 | — | — | US | disclosed |
| US-20200181118-A1 | FUSED RING COMPOUNDS | GENENTECH INC (US) | 2020-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210230142-A9 | FUSED RING COMPOUNDS | KRAS, NRAS, HRAS | NOS2 3039/4885NOS3 3408/4885NOS1 3354/4885 |
| US-20230203060-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | KRAS, NRAS, TP53 | NOS2 4814/4885NOS3 4780/4885NOS1 4726/4885 |
| US-20200181118-A1 | FUSED RING COMPOUNDS | KRAS, NRAS, HRAS | NOS2 3039/4885NOS3 3408/4885NOS1 3354/4885 |
| US-11236068-B2 | Fused ring compounds | KRAS, NRAS, HRAS | NOS2 3039/4885NOS3 3408/4885NOS1 3354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.